Biotech stocks can be some of the market’s most unpredictable movers. Breakthrough trial wins can send shares soaring overnight, while failed readouts can erase billions in market value just as fast. This is what happened with Novo Nordisk (NVO) on Monday, Nov. 24. The company’s stock has plunged sharply to its 4-year low after a closely watched Alzheimer’s trial for semaglutide failed to hit its main cognitive goal. The study had long been viewed as a “lottery ticket,” but with shares sliding to a four-year low, investors are asking whether this massive dip represents a rare buying opportunity, or a warning sign as competition intensifies and guidance cuts stack up.
For long-term investors evaluating the damage and the upside, here’s what you need to know about Novo Nordisk’s latest setback.
